Why Anavex Is Rising In Pre-market?

October 02, 2025 — 07:52 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Anavex Life Sciences (AVXL) announced positive topline results from its placebo-controlled Phase 2 clinical study evaluating ANAVEX3-71 for the treatment of schizophrenia in adults on stable antipsychotic medication. The study achieved its primary endpoint demonstrating that ANAVEX3-71 was safe and well-tolerated. The safety profile was consistent with previous studies of ANAVEX3-71 in healthy volunteers.

The company noted that, in addition to meeting the primary safety endpoint, secondary and exploratory analyses revealed encouraging trends in several outcome measures. The study showed positive trends in objective electroencephalography and event-related potential biomarkers of schizophrenia.

Shares of Anavex are up 7% in pre-market trade on Thursday.

For More Such Health News, visit rttnews.com.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Why Anavex Is Rising In Pre-market?

Tags

Latest Articles